Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 19/20 | 0.67 |
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.67 |
| ▸ | PDE6D | O43924 | 1/20 | 0.67 |
| ▸ | PDE6A | P16499 | 1/20 | 0.67 |
| ▸ | PDE6G | P18545 | 1/20 | 0.67 |
| ▸ | PDE6B | P35913 | 1/20 | 0.67 |
| ▸ | PDE6C | P51160 | 1/20 | 0.67 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.67 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.67 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14361986 | 0.87 | PDE2A (0.65) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL15745614 | 0.82 | PDE2A (0.71) | PDE2APDE10AESR2PDE4DPDE11A | |
| SCHEMBL14362264 | 0.80 | PDE2A (1.00) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL14765006 | 0.77 | PDE2A (0.81) | PDE2APDE10AESR2PDE4DPDE11A | |
| SCHEMBL12502536 | 0.77 | PDE2A (1.00) | PDE2APDE10AESR2PDE4DPDE11A | |
| SCHEMBL14473953 | 0.77 | PDE2A (0.69) | PDE2APDE10AESR2PDE4DPDE11A | |
| SCHEMBL14361900 | 0.76 | PDE2A (0.72) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL14362197 | 0.76 | PDE2A (0.81) | PDE2APDE10APDE6DPDE6APDE6G | |
| SCHEMBL12502680 | 0.75 | PDE2A (1.00) | PDE2APDE10AESR2PDE4DPDE11A | |
| SCHEMBL12503036 | 0.75 | PDE2A (1.00) | PDE2APDE10APDE4DPDE11A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | PDE2A, PDE12, PDE5A | PDE2A 1/4885PDE10A 10/4885PDE6D 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.